Telix Pharmaceuticals (ASX:TLX) has closed the 2025 financial year, having met its upgraded revenue guidance, underscoring the accelerating commercial momentum of its precision medicine portfolio and the growing impact of its U.S. expansion strategy.
For the full year ended 31 December 2025, the Melbourne-headquartered radiopharmaceutical company reported unaudited group revenue of approximately US$804 million ($1.2 billion), placing it squarely within the revised guidance range of US$800 million to US$820 million.
The company said the result reflects strong fourth-quarter performance, with revenue reaching approximately US$208 million, up 46 per cent from the same period a year earlier.
Growth was led by Telix’s Precision Medicine division, which generated approximately US$161 million in revenue during the quarter. Sequential growth of 4 per cent quarter-on-quarter was driven primarily by the successful U.S. launch of Gozellix, following reimbursement approval by the Centers for Medicare and Medicaid Services effective from October 2025. Management highlighted that revenue growth significantly outpaced dose volume increases, pointing to improved pricing dynamics and market share gains from Telix’s dual-product PSMA imaging strategy.
Chief Executive Officer Dr Christian Behrenbruch said the early uptake of Gozellix, alongside expanding integration across key U.S. accounts, has positioned the company for sustained growth into 2026. He emphasised that Telix is seeing tangible benefits from pairing its established Illuccix franchise with newer product launches, reinforcing its competitive position in the precision oncology imaging market.
Beyond commercial execution, Telix continued to advance its therapeutics pipeline during the quarter. The company treated its first international patients in the randomised expansion phase of the ProstACT Global Phase 3 study for its lead prostate cancer therapeutic candidate, TLX591-Tx. In parallel, the first U.S. patients were dosed in the SOLACE Phase 1 study evaluating TLX090-Tx for pain associated with bone metastases, marking another milestone in Telix’s transition toward therapeutic radiopharmaceuticals.
Telix also strengthened its strategic positioning through a collaboration with Varian, a Siemens Healthineers company, to explore clinical applications combining Telix’s theranostic products with external beam radiation therapy. The partnership is intended to open pathways for integrated treatment approaches, beginning with prostate cancer and potentially extending across Telix’s broader pipeline.
Internationally, the company made progress on regulatory and market expansion fronts, including broader European commercialisation of Illuccix, continued market leadership in Australia, and regulatory momentum in China and Japan. These developments align with Telix’s longer-term strategy to build a globally integrated radiopharmaceutical platform supported by in-house manufacturing and supply chain investments.